These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 21414498

  • 1. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid.
    Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM.
    J Am Acad Dermatol; 2011 Apr; 64(4):741-7. PubMed ID: 21414498
    [Abstract] [Full Text] [Related]

  • 2. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS, Sanyal S, Abraham JL.
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J.
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E, Semelka RC, Cakit C.
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T, Okada H, Horio M, Ohno I, Tamura S, Sugimoto H, Tsushima Y, Hayashi H, Fukuda K, Korogi Y, Yoshifumi N.
    Nihon Jinzo Gakkai Shi; 2009 Jul; 51(7):839-42. PubMed ID: 19928554
    [No Abstract] [Full Text] [Related]

  • 12. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE, Sviland L, Sekse I, Svarstad E.
    Tidsskr Nor Laegeforen; 2009 Jan 29; 129(3):180-2. PubMed ID: 19180161
    [Abstract] [Full Text] [Related]

  • 13. Findings of osseous sclerotic bodies: a unique sequence of cutaneous bone formation in nephrogenic systemic fibrosis.
    Kartono F, Basile A, Roshdieh B, Schwimer C, Shitabata PK.
    J Cutan Pathol; 2011 Mar 29; 38(3):286-9. PubMed ID: 20726931
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN, Gagnon AL, Darling MD, Patterson JW, Cropley TG.
    JAMA Dermatol; 2015 Oct 29; 151(10):1117-20. PubMed ID: 26017458
    [Abstract] [Full Text] [Related]

  • 16. Nephrogenic systemic fibrosis.
    Weinreb JC, Kuo PH.
    Magn Reson Imaging Clin N Am; 2009 Feb 29; 17(1):159-67. PubMed ID: 19364606
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC, Abu-Alfa AK.
    J Magn Reson Imaging; 2009 Dec 29; 30(6):1236-9. PubMed ID: 19938035
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation.
    Edgar E, Woltjer R, Whitham R, Gultekin SH, Watnick S, Cupler EJ.
    Neuromuscul Disord; 2010 Jun 29; 20(6):411-3. PubMed ID: 20462761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.